Company intelligence / Profile preview
Indapta Therapeutics
Seattle, Washington, United Statesindapta.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Indapta's lead candidate IDP-023 has received FDA Fast Track Designation for multiple myeloma and non-Hodgkin lymphoma. Preliminary results in cancer are encouraging, and the company is planning to initiate a Phase 1 trial for multiple sclerosis in Q1 2025[3][6].
- Therapeutic areas
- OncologyNeurology
- Modalities
- Natural Killer (NK) cell therapyallogeneic cell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Beyond the preview
Go deeper on Indapta Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Indapta Therapeutics.